- The latest MyBreastAI Suite* supports clinicians in
accelerating breast cancer detection, while the company’s Pristina
Bright** solution helps healthcare providers start a new contrast
program.
GE HealthCare (Nasdaq: GEHC), a leader in breast health
technology and diagnostics, will feature its latest breast cancer
detection technology during the 2024 Society of Breast Imaging
Symposium in Montreal, Canada, April 11-14, 2024. This year’s
showcase will feature the Mobile Mammography Screening
Truck, the recently released MyBreastAI Suite* and
Pristina Bright** offering to demonstrate the company’s
personalized approach to transforming breast cancer imaging.
Breast cancer is the most commonly diagnosed cancer among women,
with one in eight facing diagnosis in their lifetime.1 Regular
mammograms are critical, but their effectiveness is reduced in
women with dense breast tissue, who are four to six times more
likely to develop breast cancer.2 As a result, clinicians are
turning to supplemental screening options and artificial
intelligence (AI) technologies to help enhance the detection and
diagnosis of breast cancer, improve patient outcomes, and help with
radiology workflow so more patients can benefit from the world’s
most sophisticated mammography tools.3
GE HealthCare’s latest MyBreastAI Suite provides an
all-in-one AI platform optimized for mammography to support
clinicians with breast cancer detection. With this initial release,
MyBreastAI Suite integrates three AI applications from iCAD
including ProFound AI for DBT, SecondLook for 2D Mammography and
PowerLook Density Assessment to help support early detection and
improve patient outcomes, as well as help radiology departments
improve operational productivity.
"As part of GE HealthCare’s ongoing commitment to transform
healthcare and improve patient outcomes, we continue to explore how
we can leverage the power of AI in mammography to support the early
detection of breast cancer,” says Pooja Pathak – Vice President and
General Manager of Mammography. “We look forward to sharing this
latest tool in our portfolio of technologies for personalized
breast cancer care with the breast imaging community this year at
SBI2024.”
Contrast-Enhanced Mammography (CEM), a technology first
pioneered by GE HealthCare in 2010, is a game changer in breast
diagnostic imaging and biopsy care - with over 200 publications
that demonstrate its clinical performances.
In an effort to help further advance breast cancer and support
healthcare providers in starting a new contrast program, the
company will also be showcasing its Pristina Bright offering
- a comprehensive solution that combines SenoBright HD, Pristina
Serena, and Serena Bright with an education program that includes
dedicated on-site support, CME accredited self-assessment, and
access to a users’ club to share with experts around the globe and
leverage resources needed to market their facility among referring
doctors and patients.
With Pristina Bright, clinicians can see lesions that cannot be
seen on routine mammography4 5 6 and biopsy what is seen within 15
minutes.7 To help improve overall productivity, Pristina Bright can
also help providers take more patients on their system, with the
ability to image up to 30 patients a day with contrast mammography8
through an easy-to-read exam.
“Through our research and clinical experiences, contrast
enhanced mammography (CEM) continues to emerge as game-changer in
helping to improve breast cancer outcomes for patients facing this
difficult diagnosis,” shares Dr. Jordana Phillips – Radiologist at
Boston Medical Center. “When it comes to findings that are
difficult to define, CEM leverages the addition of a contrast agent
to highlight unusual areas of blood flow - providing an efficient
yet familiar, patient-centric approach to evaluate the presence of
cancer with high sensitivity and specificity. With contrast, we’re
able to turn a normal mammogram into something that provides so
much more information which accelerates our ability to make a
confident diagnosis. We’re excited to be joining GE HealthCare and
the breast imaging community at SBI 2024 to share more about our
experience through the hands-on learning course, as well as share
how we’ve implemented CEM as part of our efforts to provide
personalized breast cancer care to community we serve.”
As part of the company’s commitment to enabling access to
healthcare, GE HealthCare will have its mobile mammography
showcase onsite. Attendees will have the unique opportunity to
explore the capabilities of this unit designed to offer convenient
screening set-up within the familiar environment of a workplace.
The truck is equipped with the Senographe Pristina and Invenia ABUS
to ensure accurate and efficient screenings.
Visit booth 301 to learn more about GE HealthCare’s
personalized breast cancer screening solutions, including:
- Senographe Pristina, a mammography system designed to
provide a better patient experience and optimized for rapid
diagnosis;
- Invenia ABUS, the first FDA-approved automatic breast
ultrasound supplemental screening specifically designed for
detecting cancer in dense breast;
- SenoBright HD Contrast Enhanced Mammography (CEM), which
combines mammography and vascular-based screening methods to
highlight areas of unusual blood-flow patterns that may indicate
malignancy - helping reduce the masking effect of fibro glandular
breast tissue so lesions can be more clearly identifiable; and
- Serena Bright, the industry’s first contrast-guided
biopsy solution which transforms the screening room into an
interventional suite if medical indications recommend
pathology.
*MyBreastAI suite is a commercial offering
that includes GE HealthCare’s Edison Health Services platform,
ProFound AI® for DBT, SecondLook for 2D Mammography and PowerLook®
Density Assessment. These applications are provided by iCAD.
MyBreastAI Suite is compatible with the latest versions of iCAD,
Inc. as of November 14, 2023.
** Pristina Bright is a commercial
offering including SenoBright HD, Pristina Serena and Serena
Bright.
About GE HealthCare Technologies Inc.
GE HealthCare is a leading global medical technology,
pharmaceutical diagnostics, and digital solutions innovator,
dedicated to providing integrated solutions, services, and data
analytics to make hospitals more efficient, clinicians more
effective, therapies more precise, and patients healthier and
happier. Serving patients and providers for more than 125 years, GE
HealthCare is advancing personalized, connected, and compassionate
care, while simplifying the patient’s journey across the care
pathway. Together our Imaging, Ultrasound, Patient Care Solutions,
and Pharmaceutical Diagnostics businesses help improve patient care
from diagnosis, to therapy, to monitoring. We are a $19.6 billion
business with approximately 51,000 colleagues working to create a
world where healthcare has no limits.
Follow us on LinkedIn, X (formerly Twitter), and Insights for
the latest news, or visit our website https://www.gehealthcare.com/
for more information.
____________________
1 Breastcancer.org. Breast Cancer Facts
and Statistics. Available at:
https://www.breastcancer.org/facts-statistics. Last accessed March
2023.
2 Boyd NF et al. NEJM 2007; 356:
227-36.
3 Bashar, MD Abu; Begam, Nazia1. Breast
cancer surpasses lung cancer as the most commonly diagnosed cancer
worldwide. Indian Journal of Cancer 59(3):p 438-439, Jul–Sep 2022.
| DOI: 10.4103/ijc.IJC_83_21.
4 Compared to without contrast.
5 Sung JS, et al. Performance of
Dual-Energy Contrast-enhanced Digital Mammography for Screening
Women at Increased Risk of Breast Cancer. Radiology. 2019
Oct;293(1):81-88.
6 Sorin V, et al. Contrast-Enhanced
Spectral Mammography in Women With Intermediate Breast Cancer Risk
and Dense Breasts. AJR Am J Roentgenol. 2018
Nov;211(5):W267-W274.
7 Data on file. GE HealthCare 2020.
8 Over 8 hours. Data on file, GE
HealthCare 2019.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240411154571/en/
Emily Niles Global Communications Leader – Women’s Health &
X-ray M 262.290.8089 emily.niles@gehealthcare.com
GE HealthCare Technologies (NASDAQ:GEHC)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
GE HealthCare Technologies (NASDAQ:GEHC)
Historical Stock Chart
Von Mai 2023 bis Mai 2024